As geopolitical competition increasingly extends into the life sciences sector, the United States faces growing anxiety over China’s rapid ascent in global clinical drug research. While this concern is grounded in tangible data, framing reform of U.S. clinical trial systems as a zero-sum race risks overlooking a far more impactful goal: building a faster, safer, globally trusted model for medical innovation that benefits patients worldwide.
At the center of U.S. reform efforts is a new pilot program launched by the U.S. Food and Drug Administration (FDA), part of a broader initiative led by the Department of Health and Human Services. The program is designed to cut red tape for early-stage clinical trials, with projections that it could shorten overall drug development timelines by 6 to 12 months. This move comes in response to a clear, ongoing industry shift: a growing share of early-stage drug research has relocated outside U.S. borders, drawn to destinations ranging from China to Australia by lower operational costs, streamlined regulatory approval processes, targeted tax incentives and more efficient clinical trial networks.
The data behind U.S. policymakers’ concerns is stark. Federal officials confirm that China now conducts more clinical drug trials than the United States, and one 2024 estimate places China’s share of all global trials at 39 percent. This shift is far from trivial: early-stage trials are not just routine technical procedures, they are the foundational gateway to global biomedical innovation. The geographic location of these trials shapes which patient populations gain early access to cutting-edge therapies, which academic and medical institutions build specialized research expertise, where billions in global life sciences investment flows, and which nations’ regulatory frameworks ultimately set the global standard for drug development.
Despite this shifting landscape, the central question facing U.S. leaders is not whether the country can “outcompete” China on trial volume alone. Instead, it is whether the U.S. can restructure its system to be fast enough to retain and attract global research investment, rigorous enough to protect trial participants, and transparent enough to produce clinical evidence that the entire world can rely on.
The FDA’s proposed regulatory reforms move toward this goal. Under the new framework, the agency will provide pharmaceutical companies with earlier clarity on manufacturing requirements, dose selection and approval pathways, and will offer rolling review of some applications, allowing sponsors to submit materials incrementally rather than waiting to compile a full complete dossier before review begins. The FDA has also reaffirmed a new flexible approach: in select cases, a single high-quality late-stage trial, supported by robust confirmatory evidence, will be sufficient to support drug approval, replacing the longstanding requirement for two separate positive late-stage trials.
Other federal agencies are joining the push for reform. The National Institutes of Health is set to explore innovative trial designs, integrate artificial intelligence and real-world patient data into research processes, and streamline the slow, fragmented ethics review process. Federal health technology officials are also working to break down data silos, exploring how interoperable electronic health record systems can connect more diverse patient populations to research studies.
These steps are rooted in a clear diagnosis of U.S. system weaknesses. The American regulatory framework is not slow because regulators oppose innovation. Rather, friction accumulates across a series of disconnected stages: trial activation, contracting, ethics review, site selection, patient recruitment, data collection and communication between sponsors and regulators all operate as separate, uncoordinated layers. While each step was designed to serve a valid purpose, their cumulative effect creates costly delays that drive research activity overseas.
Yet the reform effort carries a key risk: if speed becomes the only overriding goal, the U.S. could trade its greatest advantage for marginal gains. If faster trials come at the cost of thinner clinical evidence, weaker patient oversight or pressure to rush enrollment to meet arbitrary timelines, the U.S. will not strengthen its global position—it will erode public trust that takes decades to build, and is far harder to recover than a compressed regulatory timeline.
When assessing China’s rise in clinical research, nuance is critical. China’s growth is not solely the result of subsidies and loose regulation. It reflects decades of deliberate, strategic investment: building dense, coordinated hospital research networks, leveraging its large diverse patient population, cultivating a growing pool of top scientific talent, and aligning industrial policy with public health goals to drive research growth. The U.S. would benefit from studying these strengths honestly rather than relying on caricature; learning from a competitor is not surrender, it is a mark of strategic maturity.
At the same time, the U.S.’s enduring core advantage has never been primarily speed—it is credibility. FDA approval decisions carry global influence precisely because, for all its imperfections, the agency is widely viewed as methodologically rigorous and comparatively transparent. Instead of copying other nations’ models, the U.S. should anchor its competitive strategy in trust, building a reformed system that prioritizes both speed and credibility.
One actionable step to achieve this is the creation of a national network of pre-certified “trial-ready” research sites. Rather than treating every study as a one-off project requiring new contracting, ethics review and data standardization from scratch, the government could certify standing research networks that already have master contracts, pre-agreed data standards, robust privacy safeguards, community engagement frameworks and shared centralized ethics review. Sponsors could connect to these networks far faster, and patients and providers would have clear visibility into which sites meet consistent quality benchmarks.
A second key reform is expanding access to trials beyond major urban elite academic centers, reducing geographic barriers to participation. When patients must travel repeatedly to specialized research centers for trial visits, enrollment remains slow and unequal, excluding large swathes of diverse patient populations. A more practical, accessible model would integrate more trial activities into routine patient care, supported by interoperable electronic health records and strengthened local research networks. This would shift clinical trials from rare, exclusionary events to a normal, accessible part of healthcare for more patients.
Policymakers also need to distinguish between two distinct forms of speed. Regulatory speed refers to shorter approval queues and clearer, earlier guidance for sponsors—this primarily benefits pharmaceutical companies by cutting development timelines and costs. Evidence speed, by contrast, refers to generating reliable clinical evidence faster through smarter trial designs, improved outcome measures, interoperable data systems, and earlier detection of treatment benefits and harms—this primarily benefits patients. A meaningful, durable reform agenda requires prioritizing both.
For the broader Asia-Pacific region, the stakes of this reform extend far beyond the U.S.-China bilateral competition. If the U.S. succeeds in pulling large volumes of trials back to domestic sites, regional research centers across Asia could face heightened competition for global investment. But a far better outcome is within reach: a global clinical research ecosystem that is more distributed, interoperable across trusted regulatory jurisdictions, rather than splitting into rival geopolitical blocs. Regulators can compete on quality and efficiency while cooperating on core shared priorities: data integrity, patient protection and universal transparency.
This collaborative model would benefit all nations: China has a clear stake in building global trust in its research output, the U.S. benefits from learning from efficient systems abroad, and patients everywhere gain faster access to therapies that have been rigorously proven safe and effective, rather than just heavily marketed.
By this standard, the FDA’s new pilot initiative should be judged against three core tests. First, does it cut unnecessary bureaucracy without lowering standards for clinical evidence? Second, does it expand access to trial participation beyond elite academic centers and large urban hospitals? Third, does it produce transparent, reproducible evidence that other nations can examine, verify and trust?
If the reforms pass these tests, the U.S. will do more than recapture market share in global clinical trial volume. It will redefine what global leadership in biomedical innovation actually means. In an era of intensifying great power competition, the most successful nation will not be the one that turns scientific research into another geopolitical battlefield. It will be the one that proves speed and public trust can advance together, for the benefit of patients across the world.
This analysis comes from Y. Tony Yang, an endowed professor at George Washington University in Washington, D.C.
